Teva CEO: 'Content' with 2/3 access of payers for migraine drug Ajovy

Teva Pharmaceutical Industries is "content" with having its new migraine drug Ajovy covered by nearly two-thirds of payers in the United States, Chief Executive Kare Schultz told Reuters on Wednesday.

from Reuters: Health News https://reut.rs/2Gpka4f
via IFTTT